Drug intelligence / Profile preview

HGP-1910

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HGP-1910 is an oral pharmaceutical agent developed by Hanmi Pharmaceutical for the treatment of primary hypercholesterolemia. It is currently under clinical investigation, with completed trials evaluating its efficacy and safety in patients with elevated cholesterol levels. The drug's precise mechanism of action has not been publicly disclosed, but it is being studied as a novel therapy within the field of endocrinology, specifically targeting lipid disorders such as hypercholesterolemia[1][2][3][4].

Beyond the preview

Go deeper on HGP-1910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGP-1910.

Explore the full profile